drug
as of 2026-07-01escitalopram
Escitalopram
MeSH D000089983
at a glance
small molecule
Pre-approval / investigational in the US
Developed by BeerYaakov Mental Health Center
7 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
7
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05603104Phase 3Recruiting
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study
NCT00708396Phase 4Unknown
Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone
NCT01119638Phase 4Completed
Escitalopram in Schizophrenia in OCD- Open Label Study
NCT00456937Phase 4Completed
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
NCT00231335Phase 4Completed
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
NCT00148447Phase 3Completed
KOLs & investigators
7
Rafael Octavio Stryjer, M.D.KOL score 5
Rafael Octavio Stryjer, MDKOL score 5
Helge Frieling, Prof., MDKOL score 5
Moshe Rehavi, Ph.D.KOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
KOL
Rafael Octavio Stryjer, M.D.
personKOL score 5
Rafael Octavio Stryjer, MD
personKOL score 5
Helge Frieling, Prof., MD
personKOL score 5
Moshe Rehavi, Ph.D.
personKOL score 5